Cellular cytotoxicity is a form of immunogenic cell death

por Minute, Luna, Teijeira, Alvaro, Sanchez-Paulete, Alfonso R, Ochoa, Maria C, Alvarez, Maite, Otano, Itziar, Etxeberrria, Iñaki, Bolaños, Elixabet, Azpilikueta, Arantza, Garasa, Saray, Casares, Noelia, Luis Perez Gracia, Jose, Rodriguez-Ruiz, Maria E, Berraondo, Pedro, Melero, Ignacio
Publicado 2020

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

por Glez-Vaz, Javier, Azpilikueta, Arantza, Olivera, Irene, Cirella, Assunta, Teijeira, Alvaro, Ochoa, Maria C, Alvarez, Maite, Eguren-Santamaria, Iñaki, Luri-Rey, Carlos, Rodriguez-Ruiz, Maria E, Nie, Xinxin, Chen, Lieping, Guedan, Sonia, Sanmamed, Miguel F, Luis Perez Gracia, Jose, Melero, Ignacio
Publicado 2022

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

por Gomez-Roca, Carlos, Cassier, Philippe, Zamarin, Dmitriy, Machiels, Jean-Pascal, Luis Perez Gracia, Jose, Stephen Hodi, F, Taus, Alvaro, Martinez Garcia, Maria, Boni, Valentina, Eder, Joseph P, Hafez, Navid, Sullivan, Ryan, Mcdermott, David, Champiat, Stephane, Aspeslagh, Sandrine, Terret, Catherine, Jegg, Anna-Maria, Jacob, Wolfgang, Cannarile, Michael A, Ries, Carola, Korski, Konstanty, Michielin, Francesca, Christen, Randolph, Babitzki, Galina, Watson, Carl, Meneses-Lorente, Georgina, Weisser, Martin, Rüttinger, Dominik, Delord, Jean-Pierre, Marabelle, Aurelien
Publicado 2022